



TBVI Symposium 2025

January 28-29, 2025

Tuesday January 28, 2025 (*Maison des congrès, Les Diablerets*)

13.30-13.40 Welcome and Opening - Stefan Kaufmann, Governance Board TBVI

13.40-13.55 TBVI Awards 2025 – Ole Olesen, TBVI

1. Innovating and diversifying the TB vaccine pipeline - Challenges in TB vaccine design

chair: Olivier Neyrolles

13.55-14.00 Introduction (chair)

14:00-14.30 [“The enigmatic role of CD8 T cells in immunity to tuberculosis”](#), Sam Behar, University of Massachusetts Chan Medical School

14.30-14.50 “Overview on efforts & findings on identifying relevant B cell antigens”, Natalia Freund Tel Aviv University

14.50-15.10 “Parallels and deviations in natural and vaccine-induced immunity against TB”. TBVI awardee Andrew Simonson, University of Pittsburgh.

15:10-15.25 Q&A

15.25-15.55 Coffee break and Group photo

15.55-16.15 [“New adjuvants for TB vaccines”](#), Kris Short (VFI) and Elena Stylianou University of Oxford

16:15-16.35 “Novel TLR7 adjuvant: a potential alternative for TB vaccines”, Akihisa Fukushima Sumitomo Pharma

16.35-16.50 Q&A

16.50-17.10 Coffee break

2. Accelerating TB vaccine development

chairs: Elly van Riet and Marit Holleman

17.10-17.30 [“WHO priority activities for new TB vaccines in 2025”](#), Birgitte Giersing, WHO

17.30-17:45 Introduction TB Vaccine Development Pathway, Elly van Riet and Marit Holleman, TBVI

17:45-18:25 Panel discussion on the TB Vaccine Development Pathway – Preclinical
Chaired by Ann Ginsberg (BMGF)
Panel members: Louis Ates (BioNTech), Simon Clark (UKHSA), Frank Verreck (BPRC)

18.25-18.30 Wrap-up & summary, outlook to Wednesday

19.00-20.00 Reception

20.00 Joint dinner



TBVI Symposium 2025

January 28-29, 2025

Wednesday January 29, 2025 (*Maison des congrès*)

08.25-08.30 Welcome and programme of the day - Elly van Riet, TBVI

3. Accelerating Clinical Development

Chairs: Frank Cobelens (AIGHD) and Mark Hatherill (SATVI)

- 08.30-08.50 [Preclinical development of mRNA-based tuberculosis vaccines – How BNT164 applies learnings from Comirnaty](#), Louis Ates, BioNTech
- 08.50-09.10 Updates on the VPM1002 clinical trial, Sina Bruckner, SLS-Europe
- 09.10-09.30 The M72/AS01E Phase 3 trial: challenges, opportunities, and lessons learned, Alex Schmidt, GMRI
- 09.30-09.50 [MTBVAC against TB, reaching its last stages](#), Ingrid Murillo, Biofabri
- 09.50-10.20 Panel discussion on the TB Vaccine Development Pathway - Clinical Trial Design
Chaired by Frank Cobelens and Mark Hatherill
Panel members: Dhananjay Kapse (SII), Alex Schmidt, Ingrid Murillo, Gavin Churchyard (Aurum)
- 10.20-10.50 Coffee break**

4. Community Engagement and Inclusive Clinical Development

chair: Elly van Riet

- 10.50-11.10 [Lessons vaccine researchers and developers could learn from the observed suboptimal responses to vaccines, specifically for TB](#), Abena Amoah, Hypovax
- 11.10-11.30 TBVI Awardee Beatrice Francis, universities of Makerere and Oxford, "[Factors influencing immunogenicity of tuberculosis vaccines in Ugandan adolescents](#)"
- 11.30-11.50 "[SATVI – 23 years of TB research](#)", Michele Tameris, SATVI
- 11.50-12.10 "[Capacity building and community engagement for TB vaccine trial in LMIC: experience from Madagascar](#)", Niaina Rakotosamimanana, IPM
- 12.10-12.25 Q&A
- 12.25-12.30 Closure, Ole Olesen